Formycon AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on the stock and has a €48.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yi Chen’s rating is based on several strategic developments surrounding Formycon AG. The resolution of patent disputes with Regeneron Pharmaceuticals regarding the Eylea biosimilar FYB203 has paved the way for its anticipated U.S. launch in the fourth quarter of 2026, providing a clear commercial timeline. This settlement not only resolves legal uncertainties but also enhances investor confidence in the company’s future prospects.
Additionally, Formycon’s strategic partnerships, such as the agreement with Horus Pharma for commercialization in selected European countries, are expected to maximize market penetration. The dual-brand strategy in Europe, combined with Formycon’s role in organizing the supply chain, positions the company to capitalize on its biosimilar products effectively. Furthermore, the ongoing Dahlia trial for FYB206 and its potential market entry post-2029 add to the company’s growth potential, supporting the Buy rating.
According to TipRanks, Chen is an analyst with an average return of -4.7% and a 43.61% success rate. Chen covers the Healthcare sector, focusing on stocks such as VolitionRX, Anixa Biosciences, and RegenXBio.
In another report released on October 2, Kepler Capital also maintained a Buy rating on the stock with a €50.00 price target.